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AbstrACt
Objectives The coverage of prevention of mother- to- child 
transmission (PMTCT) services in South Africa is variable. 
Identifying gaps in the implementation of these services 
is necessary to isolate steps needed to further reduce 
paediatric infections and eliminate transmission.
setting Two primary care clinics in Paarl, South Africa.
Participants 1225 pregnant women; inclusion criteria 
were 18 years or older, clinic attendance and remaining in 
area for at least 1 year.
Methods Data were collected through the Drakenstein 
Child Health Study, a population- based birth cohort in 
a periurban area of the Western Cape, South Africa. A 
combination of clinic records, hospital records, national 
database searches and maternal self- report were collected 
during the study.
results Of the 1225 mothers enrolled in the cohort 
between 2012 and 2015, 260 (21%) were confirmed 
HIV infected antenatally and 1 mother tested positive 
in the postnatal period. Of those with documentation 
(n=250/260, 96%), the majority (99%) received 
antiretroviral prophylaxis or therapy (ART) before labour; 
however, there was a high rate of defaulting from ART 
noted during pregnancy (20%). All HIV- exposed infants 
with data received antiretroviral prophylaxis, 35% were 
exclusively breast fed until 6 weeks and 16% for 6 months. 
There were two cases of infant HIV infection (0.8%) who 
were initiated on ART but had complicated histories.
Conclusion Despite the low transmission rate in this 
cohort, reaching elimination will require further work, 
and this study illustrates several areas to improve 
implementation of PMTCT services and reduce paediatric 
infections including retesting at- risk HIV- negative mothers 
through the duration of breast feeding, infant HIV testing at 
any admission in addition to routine testing and improved 
counselling to prevent defaulting from treatment. Better 
data surveillance systems are essential for determining the 
implementation of PMTCT guidelines.
IntrOduCtIOn
In the past decade, there has been wide-
spread progress globally in the prevention 
of mother- to- child transmission (PMTCT) of 
HIV and in 2014, the WHO launched the call 
for elimination of mother- to- child transmis-
sion (MTCT) of HIV.1 Countries must meet 
specific criteria to achieve elimination status, 
including ≤50 new paediatric infections per 
100 000 live births. For countries with high 
prevalence of antenatal HIV, these targets are 
very challenging and will only be achieved 
with extremely low transmission rates 
requiring almost total coverage of a compre-
hensive package of PMTCT interventions.
South Africa has the highest number of 
HIV- infected people in the world with preva-
lence rates of up to 40% among public ante-
natal clinic attendees.2 In 2010, the Western 
Cape government rolled out guidelines, 
which, based on a pregnant woman’s clinical 
and immunological status, provided antiret-
roviral therapy (ART) for life or zidovudine 
(AZT) starting at 14 weeks gestation (option 
strengths and limitations of this study
 ► This study quantifies the implementation and up-
take of prevention of mother- to- child transmission 
(PMTCT) guidelines in the current era identifying key 
gaps to inform how we may achieve very high cov-
erage of a package of effective PMTCT interventions 
that will further reduce transmissions in high preva-
lence settings and achieve elimination.
 ► This research was conducted within a birth cohort 
study, whose primary aim was not to study HIV and 
PMTCT, providing a more natural study of implemen-
tation but with increased attention on data quality.
 ► The women included in these analyses were en-
rolled in a birth cohort study and may have been 
more uniquely motivated to attend clinics and en-
gage in care than women not enrolled in the study, 
and thus these results may indicate a ‘best case’ 
scenario for engagement in PMTCT interventions.
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A). In 2013, the Western Cape government rolled out 
option B+, which provides ART for life for all pregnant 
women regardless of CD4 T- cell count. The first- line 
regimen is triple therapy, comprising a non- nucleoside 
reverse- transcriptase inhibitor and two nucleoside reverse 
transcriptase inhibitors. Previous research, however, has 
shown that PMTCT service coverage in South Africa 
is variable, leading to missed opportunities for further 
reduction of transmission.3
A recent national evaluation4 of the PMTCT 
programme showed a 6- week MTCT rate of 2.6% rising 
to 4.3% at 18 months post partum, indicating the need 
to further explore the actual implementation of PMTCT 
programmes in South Africa. Lessons from the implemen-
tation and uptake of PMTCT guidelines in the current 
era are necessary to inform how we may achieve very high 
coverage of a package of effective PMTCT interventions 
that will further reduce transmissions in high prevalence 
settings and achieve elimination. In this report, we sought 
to quantify the implementation of PMTCT guidelines 
using data from the Drakenstein Child Health Study,5 6 a 
population- based birth cohort in a periurban area of the 
Western Cape, South Africa.
MethOds
The Drakenstein Child Health Study recruited women 
during their second trimester of pregnancy (20–28 weeks 
gestation) from two community- based antenatal clinics in 
Paarl, South Africa.5 6 Women were eligible for the study if 
they attended one of the two study clinics, planned to stay 
in the study area for at least 1 year and were 18 years or 
older. All participants provided informed consent, prior 
to participation in any study activities and were enrolled 
between 2012 and 2015.
data collection
Sociodemographic information was collected during the 
antenatal visit at 28–32 weeks gestation using structured 
interviews administered by trained study staff including: 
maternal age, education, marital status, employment and 
pregnancy planning.
HIV data were collected by triangulating clinic and 
hospital folder information and through self- report 
interviews completed with mothers during the antenatal 
period, at birth and post partum. Maternal HIV diag-
nosis was established at enrolment by self- report and 
confirmed during routine HIV testing of women in preg-
nancy as per the Western Cape PMTCT guidelines.7 8 All 
HIV- infected mothers were enrolled into the Provincial 
PMTCT programme. As the recruitment for the cohort 
spanned changes in the Provincial PMTCT guidelines, 
mothers were initiated on ART per guidelines at the time: 
Option A before 2013, moving to option B+ in May 2013.
CD4 and viral load results were accessed from folder 
review and the online National Health Laboratory Service 
(NHLS) system. Where there was more than one result, 
the result closest to birth was used. ART was dichotomised 
into first and second/third- line treatment, where the 
antiretroviral drug combinations relative to the guide-
lines at the time were used. Where available, data on 
regimen switching and treatment defaulting during preg-
nancy were also obtained. Defaulting was defined as an 
interruption (or discontinuation) of ART for at least a 
month during the index pregnancy.
Infant PMTCT data were obtained from infant clinic 
folder review and HIV test results from the NHLS system. 
Infant feeding method was obtained through self- report 
from mothers at 6 weeks, 10–14 weeks and 6 months post 
partum as previously reported.9 Infant feeding was cate-
gorised into exclusive breast feeding, formula feeding or 
mixed breast feeding (breast feeding plus formula milk 
and/or solids). Ns, percentages, medians and interquar-
tile ranges are reported for all variables of interest.
Patient and public involvement
At the outset of the Drakenstein Child Health Study, 
close relationships were established with key stakeholders 
including Western Cape Government Health Department 
clinical and administrative staff and community members. 
Patients were not involved in the design or recruitment 
of the study, but at the 12 months postnatal study, visit 
participants were asked about their overall experiences 
with the study including experiences with study informa-
tion, staff, procedures and how expectations about the 
study matched their experiences.10 This information was 
used to reassess study protocols and to make alternations 
to improve study experience and participant satisfac-
tion. Patients are not currently involved in dissemination 
plans, however, study findings are routinely fed back to 
the community and the Department of Health clinical 
and administrative staff.
results
A total of 1225 women enrolled in the study. Overall, 260 
(21%) pregnant women were confirmed to be HIV posi-
tive through antenatal hospital and clinic chart reviews 
(figure 1). At enrolment, women living with HIV were on 
average 29.1 years (SD=5.3), 25% were employed, 26% 
had completed secondary education and 59% of preg-
nancies were unplanned.
Maternal interventions
Of the known women living with HIV with available data, 
the majority (182/255, 71%) knew their HIV status prior 
to the study pregnancy (table 1). One mother serocon-
verted in the postnatal period and thus, does not have 
antenatal PMTCT data. During the study pregnancy, most 
women had a CD4 T- cell count test (205/260; 79%), and 
the median CD4 count was 411 cells/mm3 (IQR: 286–609) 
with 40% (82/205) having a CD4 of <350 cells/mm3. Viral 
loads were available for 57% (148/260) of participants 
and most were undetectable (<40 copies/mL) (71%; 
105/148). Prior to the 2013 guidelines, viral load testing 
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Figure 1 Flow of participants through the Drakenstein 
Child Health Study. †Postnatal testing of women was 
not conducted through the cohort. Change in HIV status 
post partum was reported by women during detailed data 
collection about changes in their medical history at multiple 
time points.
Table 1 Maternal PMTCT results
Variable (n, %) Total (n=260)
HIV diagnosis time point*
  Before pregnancy 182 (71.4)
  During pregnancy 72 (28.2)
  After birth 1† (0.4)
CD4 (during pregnancy)
  CD4 cells/mm3 (median) (IQR) 411 (286–609)
  ≥500 cells/ mm3 78 (30.0)
  350–500 cells/mm3 45 (17.3)
  <350 cells/mm3 82 (31.5)
  No CD4 reported during pregnancy 55 (21.2)
Viral load (VL) (during pregnancy)
  Virally unsuppressed (≥1000 copies/mL) 15 (5.8)
  VL detectable (≥40–1000 copies/mL) 28 (10.8)
  VL lower than detectable limit (<40 
copies/mL)
105 (40.4)
  No VL reported during pregnancy 112 (43.1)
ART initiation*
  Before pregnancy 98 (39.2)
  During pregnancy 150 (60.0)
  Received ARVs during labour only 2 (0.8)
ART regimen during pregnancy*
  PMTCT prophylaxis (AZT (zidovudine)) 39 (15.6)
  First- line ART (triple therapy) 195 (78.0)
  Second /third- line ART 14 (5.6)
  ARVs during labour only 2 (0.8)
ART regimen switched during pregnancy* 10 (4.0)
Evidence of defaulting any time during 
pregnancy*
49 (19.6)
Missing data: HIV diagnosis time point n=6; Antiretroviral therapy 
variables n=10.
*Percentages are calculated out of available data.
†This mother was diagnosed outside of the PMTCT pathway and 
as such she is not included in the other variables in this table.
ART, antiretroviral therapy; AZT, zidovudine;PMTCT, prevention of 
mother- to- child transmission; VL, viral load.
was not routine during pregnancy and breast feeding for 
those on lifelong ART.
The majority of women received antiretroviral drugs 
during pregnancy (248/250; 99%; 10 missing data), 39 
(16%) were on PMTCT antiretroviral prophylaxis as 
per option A (AZT), 195 (78%) were on first- line triple 
ART and 14 (6%) on second/third line. Two partici-
pants (0.8%) only received treatment during labour. 
There was evidence of defaulting from ART among 49 
women (20%). Defaulters were not significantly different 
from non- defaulters by age, education, employment or 
unplanned pregnancy.
Infant interventions
Of the 260 mothers, 5 had miscarriages/in utero deaths 
(including 1 set of twins), 11 were lost to follow- up before 
birth, and there were 248 recorded live births with 4 sets 
of twins (table 2). Of the live births, all infants with data 
were recorded as receiving prophylaxis; the majority of 
infants (211/242; 87%) received nevirapine. Six infants 
(2%) did not have data post partum, and receipt of ART 
prophylaxis is unknown. Only 35% (82/235) of mothers 
living with HIV reported exclusive breast feeding at 6 
weeks post partum and 16% (37/235) for 6 months. A 
concerning 5.5% of mothers reported mixed feeding 
(breast feeding plus formula milk and/or/solids) at 6 
weeks post partum, rising to 12% by 3 months.
A total of 239 (96%) infants completed HIV PCR 
testing at 6–10 weeks post partum, which were all nega-
tive. At 9 months, 195 infants had HIV testing (79%); 
of these, 194 (99.5%) were negative and 1 (0.5%) was 
equivocal with a repeat test that was negative. As part of 
the larger cohort study, 18- month tests were followed up 
prospectively. Of the children who were still in the cohort 
at 18 months (n=220), 194 had a negative 18 month test, 
22 had a negative test postcessation of breast feeding or 
were formula fed, 3 moved out of the area and 1 tested 
equivocal and then confirmed HIV positive. There was 
also testing that occurred outside of these standard tests 
when infant symptoms warranted testing. During these 
tests, one infant tested HIV positive.
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Table 2 Child PMTCT results
Variable (n, %)
Infant birth outcomes Total (n=265)
  Live births 248 (93.6)
  Stillbirths/miscarriages/in utero deaths 6 (2.3)
  Mothers lost to follow- up before/at birth 11 (4.2)
Infant PMTCT outcomes Total (n=248)
Infant prophylaxis*   
  NVP prophylaxis 211 (87.2)
  NVP+AZT prophylaxis 31 (12.8)
Feeding method at 6 weeks*   
  Exclusively breast feeding 82 (34.9)
  Mixed feeding 13 (5.5)
  Formula feeding 140 (59.6)
Infant testing   
6–10 weeks post partum   
  Positive 0 (0)
  Negative 239 (96.4)
  No test reported 9 (3.6)
9 months post partum   
  Positive 0 (0)
  Negative 194 (78.2)
  Equivocal, repeat test negative 1 (0.4)
  No test reported 53 (21.4)
HIV positive   
  Yes 2 (0.8)†
*Percentages are calculated out of available data for live births in 
follow- up. Missing data: infant prophylaxis n=6; feeding method 
n=13.
†One infant born to newly diagnosed HIV- positive mother.
AZT, zidovudine; NVP, nevirapine.
Mother-to-child transmission
Two infants in the cohort were confirmed HIV infected, 
translating to an MTCT rate of 0.8% (2 infants/261 
mothers). In one case, the infant was born to a known 
HIV- infected mother with documented poor compli-
ance to ART, poor maternal health and very poor social 
support structures. She booked at 18 weeks and had 
repeated viral load monitoring during pregnancy and 
post partum, which showed an unsuppressed viral load 
throughout pregnancy and breast feeding; she had 
already failed first- line therapy. The child was born at 39 
weeks gestation. The mother opted for breast feeding, 
and the infant was covered with nevirapine prophylaxis; 
however, it is unclear if this was for the duration of exclu-
sive breast feeding. Although the 6–10 weeks PCR and 9 
months rapid test were negative, the infant had a positive 
rapid test at 18 months and was subsequently confirmed 
HIV positive by PCR and started on ART. However, both 
mother and child defaulted treatment and had to be 
restarted.
In the second case the mother tested HIV negative in 
the first trimester at booking (14 weeks) but subsequent 
testing was never done. The infant was born premature at 
34 weeks gestation via vaginal delivery with a birth weight 
of 1.2 kg and was not managed according to PMTCT 
protocols, as the child was considered unexposed. Exclu-
sive breast feeding was initiated, but the mother switched 
to formula feeding shortly after hospital discharge. Both 
mother and infant tested positive at 4 months of age 
when the infant was hospitalised with recurring pneu-
monia and was subsequently initiated on ART. This child 
was later diagnosed with tuberculosis and then developed 
drug- induced hepatitis and required specialist treatment.
dIsCussIOn
This study has shown a low rate of MTCT (0.8%) and 
reports on the entire PMTCT cascade with follow- up to 
18 months. This may be due to the successful implemen-
tation of PMTCT guidelines in this periurban commu-
nity, as demonstrated by the high rates of treatment in 
pregnant women and high rates of infant testing with low 
loss to follow- up compared with what has been previously 
reported.11 However, one- fifth of women defaulted from 
antiretroviral drugs at some point during pregnancy, 
indicating a need for improved adherence counselling. 
Furthermore, nearly one- third of the sample had a CD4 
T cell count of <350 with a large majority of women diag-
nosed prepregnancy, underscoring the importance of 
further focus on HIV care for women in general, outside 
of pregnancy.
Of the two HIV transmissions that occurred, both were 
identified after the 6–10 week infant PCR test. One trans-
mission was to a known high- risk mother and the other to 
a mother diagnosed during the postnatal period. These 
findings highlight several gaps to address to achieve 
PMTCT goals. These include the importance of recog-
nising high- risk mothers (eg, maternal poor adherence, 
first- line treatment failure, persistent unsuppressed viral 
loads) and providing increased support and careful 
follow- up of these mother–infant pairs throughout the 
duration of extended breast feeding.12 Second, these 
findings increase awareness of infants and mothers who 
are diagnosed following symptomatic presentation and 
not via routine testing. These data reinforce the need 
to have a ‘belts and braces’ approach to infant testing, 
including HIV testing at any infant admission in addi-
tion to routine testing.13 Third, it is important to retest 
HIV negative women during later pregnancy, during 
labour and during the breastfeeding period when women 
are at continued risk of transmitting acute infections to 
their infants. Fourth, pre- exposure prophylaxis, an effec-
tive form of HIV prevention, should be considered for 
at- risk HIV negative breastfeeding mothers in combina-
tion with standard sexual risk reduction methods. Finally, 
our sample had low rates of education and high rates 
of unplanned pregnancies, which are likely indicative 
of structural factors that may indirectly impede PMTCT 
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efforts, underscoring the need to focus on broader 
contextual contexts in addition to clinical efforts.
Data were obtained through a combination of clinic 
records, hospital records, national database searches 
and maternal self- report. Despite this exhaustive search, 
there were some missing data, indicating issues with 
PMTCT surveillance systems, a key foundational factor 
to achieving elimination of transmission. Although South 
Africa’s NHLS system tracks CD4 and viral load testing 
results, integrated data systems that track adherence to 
all PMTCT guidelines and can account for movement 
between clinical facilities are lacking. Furthermore, 
systems such as NHLS are themselves an underused tool 
for tracking individual adherence to PMTCT guidelines. 
Training and resources are needed at the clinic level to 
identify and trace patients who may be missing these key 
PMTCT services.
There are some limitations to this study that should be 
considered. The women included in these analyses were 
enrolled in a birth cohort study and may have been more 
uniquely motivated to attend clinics and engage in care 
than women not enrolled in the study. Due to the eligi-
bility criteria of the birth cohort study, participants had to 
present to the antenatal clinic in their second trimester. 
Thus, these results may indicate a ‘best case’ scenario 
for engagement in PMTCT interventions by excluding 
mothers living with HIV who are late presenters. Addi-
tionally, postnatal HIV testing of women who previously 
tested negative occurred outside of study procedures and 
was obtained through self- reports of significant maternal 
medical changes. Thus, the one mother who reported 
a postpartum diagnosis is potentially an underestimate 
for our cohort. Finally, this study, conducted in only two 
communities in the periurban area of Paarl, Western 
Cape, limiting our sample size of mothers living with HIV 
and the generalisability to other regions of the Western 
Cape or to other parts of South Africa. The Western Cape 
has some of the longest running PMTCT programme in 
South Africa and has some of the lowest MTCT rates in 
South Africa.14 Our study highlights that even in areas 
where PMTCT programme are well functioning, there 
are still areas for improvement particularly in the context 
of elimination of MTCT.
COnClusIOn
Although South Africa does not currently meet the 
criteria for elimination of MTCT, this study demonstrates 
that attaining extremely high levels of PMTCT coverage 
to further reduce transmission rates in high prevalence 
regions may be within reach. This may be achieved 
through retesting, breast feeding and ART adherence 
support, reinforced by improved data surveillance 
systems.
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